These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17457461)

  • 21. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 22. [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)].
    Wirth A
    MMW Fortschr Med; 2006 Nov; 148(46):17. PubMed ID: 17615781
    [No Abstract]   [Full Text] [Related]  

  • 23. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 24. Rimonabant in obese patients with type 2 diabetes.
    Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
    Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
    [No Abstract]   [Full Text] [Related]  

  • 25. Special report on the Sanofi-Aventis cardiometabolic symposium.
    Cardiovasc J Afr; 2007; 18(3):192-5, 198-200, 202. PubMed ID: 17612757
    [No Abstract]   [Full Text] [Related]  

  • 26. [Rimonabant. Risk of depression has not been finally clarified].
    Kreutzkamp B
    Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
    [No Abstract]   [Full Text] [Related]  

  • 27. Rimonabant in obese patients with type 2 diabetes.
    Shapiro H; Singer P
    Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
    [No Abstract]   [Full Text] [Related]  

  • 28. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    Lupica CR; Riegel AC
    Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

  • 31. Cannabinoid-1 receptor antagonists in type-2 diabetes.
    Scheen AJ
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome.
    Griffing GT
    MedGenMed; 2006 Oct; 8(4):7. PubMed ID: 17415289
    [No Abstract]   [Full Text] [Related]  

  • 33. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.
    Cervino C; Pasquali R; Pagotto U
    Mini Rev Med Chem; 2007 Jan; 7(1):21-30. PubMed ID: 17266634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New obesity and metabolic syndrome treatment: rimonabant].
    Makoundou V; Golay A
    Rev Med Suisse; 2006 Jan; 2(47):41-5. PubMed ID: 16465944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
    Kapoor S
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):339. PubMed ID: 18625002
    [No Abstract]   [Full Text] [Related]  

  • 37. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of rimonabant on weight reduction and cardiovascular risk.
    Esposito K; Giugliano D
    Lancet; 2005 Jul 30-Aug 5; 366(9483):367-8; author reply 369-70. PubMed ID: 16054931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.